today's Pick
Ebola vaccine trials being fast-tracked: researchers
Publish Date: Aug 28, 2014
Ebola vaccine trials being fast-tracked: researchers
Nigeria warns against complacency in Ebola fight A man reads a poster raising awareness on the Ebola virus reading "the risk of Ebola is still there. Let us apply the protective measures together" in Abidjian, Ivory Coast
  • mail
  • img
newvision

Safety trials on an Ebola vaccine are being fast-tracked, meaning it could be given to healthy volunteers as early as September, researchers said Thursday.

The vaccine will be given to volunteers in Britain, the Gambia and Mali in a bid to tackle the spread of an epidemic which has spread across west Africa, killing 1,552 so far.

Researchers hope the trials could finish by the end of 2014.

If they are successful, the vaccine could then be given to people infected with Ebola, which is spread through bodily fluids.

The move was announced by pharmaceuticals giant GlaxoSmithKline -- which is developing the vaccine with the US National Institutes of Health (NIH) -- and London-based medical charity Wellcome Trust, which is contributing to a grant to pay for the trials.

"A candidate Ebola vaccine could be given to healthy volunteers in the UK, the Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines," the statement said.

A total of 3,062 cases have so far been reported but the World Health Organization warned Thursday that the caseload could eventually exceed 20,000.

The trials, which still need ethical and regulatory approval, will be funded by a £2.8 million (3.5 million euro, $4.6 million) grant from the Wellcome Trust, Britain's Medical Research Council (MRC) and the UK Department for International Development (DFID).

The Oxford study will involve 60 healthy volunteers, while those in the Gambia and Mali will each involve 40.

This will also allow GSK to make some 10,000 extra doses of the vaccine so that if the trials are successful, it could be made available to the WHO quickly.

Safety tests of the vaccine will take place at Oxford University alongside a US trial run by the National Institute of Allergy and Infectious Diseases. AFP  (NIAID). AFP

The statements, comments, or opinions expressed through the use of New Vision Online are those of their respective authors, who are solely responsible for them, and do not necessarily represent the views held by the staff and management of New Vision Online.

New Vision Online reserves the right to moderate, publish or delete a post without warning or consultation with the author.Find out why we moderate comments. For any questions please contact digital@newvision.co.ug

  • mail
  • img
blog comments powered by Disqus
Also In This Section
Burkina gov
Burkina Faso's interim leaders were expected to unveil a new government lineup on Sunday, with the country anxious to see the extent of military influence under civilian President Michel Kafando....
Boko Haram gunmen kill 48 fish vendors
Boko Haram gunmen killed 48 fish vendors in Nigeria''s restive Borno State, near the border with Chad....
3000 evacuated after WWII bomb found in France
The 250-kilogramme (550-pound) bomb was found near the city's town hall during the building of a new metro line....
The Indonesian Football Association banned 12 players and officials who competed to score own-goals in a farcical match last month....
The city that has banned noisy suitcases
Famed for the serene silence of its timeless nooks and crannies, Venice is about to get even quieter ... by banning noisy suitcases on wheels....
President Yoweri Museveni has warned that if corruption in Uganda goes unchecked and unpunished, it would pose a serious threat to the country....
Should workers be subjected to a 4% Health Insurance Tax??
Yes
No
Can't Say
follow us
subscribe to our news letter